Mr. Dan Segal

• 
  www.sec.gov/Archives/edgar/data/1123011/0001001277-07-0 - [Cached Version]
  Published on: 2/28/2007    Last Visited: 3/27/2007  

  0001123011 SEGAL DANIEL C/O THERMOGENESIS CORP 2711 CITRUS ROAD RANCHO CORDOVA CA 95742 0 1 0 0 VP Sales & Marketing

• 
  www.sec.gov/Archives/edgar/data/811212/0001001277-04-00 - [Cached Version]
  Published on: 10/28/2004    Last Visited: 2/1/2005  

  Dan Segal was the V.P. of Sales and Marketing with the Company until leaving in September 2004.Mr. Segal had been with the Company since 1997 and held various positions including Director of Sales & marketing Blood Products and Director of Corporate Sales.Mr. Segal assumed the position of V.P. Sales/Marketing in August 2000.Mr. Segal graduated from Sonoma State College with a B.A. in Business Management.

• 
  www.iptoday.com/news-archived-article.asp?id=65&type=ip - [Cached Version]
  Published on: 3/12/2007    Last Visited: 4/5/2007  

  "Protection of our proprietary technology is a critical element of our growth strategy and essential to our competitive strength," said Dan Segal, Vice President of Sales and Marketing, Cell Therapy.

• 
  www.sec.gov/Archives/edgar/data/1123011/0001001277-07-0 - [Cached Version]
  Published on: 2/20/2007    Last Visited: 3/22/2007  

  0001123011 SEGAL DANIEL C/O THERMOGENESIS CORP. 2711 CITRUS ROAD RANCHO CORDOVA CA 95742 0 1 0 0 VP Sales & Marketing

• 
  www.thermogenesis.com/newsroom/index.asp - [Cached Version]
  Published on: 10/11/2008    Last Visited: 3/14/2007  

  ThermoGenesis Corp. Names cell therapy device sales expert Daniel A. Segal as Vice President of Sales & Marketing

• 
  www.sec.gov/Archives/edgar/data/811212/0001001277-02-00 - [Cached Version]
  Published on: 12/5/2002    Last Visited: 12/8/2002  

  Dan Segal
  ...
  Mr. Coelho, Mr. Acosta, Dr. Godsey, Ms. Ruecker and Mr. Segal have entered into employment agreements with THERMOGENESIS CORP.
  ...
  Mr. Dan Segal has been with THERMOGENESIS CORP since 1997 and has held various positions including Director of Sales & Marketing Blood Products and Director of Corporate Sales.Mr. Segal assumed the position of V.P. Sales/Marketing in August 2000.Mr. Segal's experience prior to joining THERMOGENESIS CORP includes over 13 years in the Specialty Surgical Device & Implant market and 2 years in the blood processing products market, where he held various positions in Sales & Marketing.Mr. Segal graduated from Sonoma State College with a BA in Business Management.KEY EMPLOYEE Ms. Michelle J. Badal, RAC, joined THERMOGENESIS CORP in May 2000 as the Director of Regulatory Affairs and Quality Systems.In her position at ThermoGenesis Corp., she manages the regulatory, quality and clinical departments.
  ...
  Coelho and Segal during fiscal year 2002.
  ...
  Dan Segal, V.P.
  
  Sales/Marketing
  
  ...
  In May 2002, THERMOGENESIS CORP renewed it's employment agreement with Mr. Dan Segal whereby Mr. Segal agreed to serve as Vice President of Sales/Marketing and receive compensation equal to $148,575 subject to annual increases as may be determined by the Board of Directors.Mr. Segal is eligible to receive bonuses based on his performance and the attainment of objectives established by the Company.Mr. Segal's bonuses shall not exceed thirty-five percent of his base salary in effect for any given year and shall be subject to Compensation Committee oversight for meeting stated objectives.The employment agreement may be terminated prior to the expiration of the agreement, upon the mutual agreement of THERMOGENESIS CORP and Mr. Segal.In addition, the employment agreement provides that in the event Mr. Segal is terminated other than "for cause" upon a change of control, Mr. Segal will be paid an amount equal to three times his annual salary.The phrase "change of control" is defined to include (i) the issuance of 33% or more of the outstanding securities to any individual, firm, partnership, or entity, (ii) the issuance of 33% or more of the outstanding securities in connection with a merger, or (iii) the acquisition of THERMOGENESIS CORP in a merger or other business combination.The employment agreement, as extended, expires by its terms in August 2005. Options Granted in Last Fiscal Year Individual Grants Officers and Directors
  
  - ---------------------------------------------------------------------------
  --------------------------------------------- Percent of otal Options
  ...
  Dan Segal
  ...
  Dan Segal

• 
  sacramento.bizjournals.com/sacramento/gen/executive.htm - [Cached Version]
  Published on: 10/11/2008    Last Visited: 3/10/2008  

  Dan SegalSacramento Business Journal: Dan Segal Executive Profile
  ...
  Dan Segal
  
  Vice President, Sales & Marketing Thermogenesis Corp

• 
  sacramento.bizjournals.com/sacramento/gen/company.html? - [Cached Version]
  Published on: 10/11/2008    Last Visited: 3/10/2008  

  Dan Segal [Vice President, Sales & Marketing] Total Executives : 7 - Get All Executive Info with our Premium Product

• 
  BayBio - Industry News - [Cached Version]
  Published on: 2/15/2007    Last Visited: 2/22/2007  

  ThermoGenesis Corp. announced that it appointed Daniel A. Segal as Vice President of Sales and Marketing in its Cell Therapy business, effective February 19, 2007.Mr. Segal returns to the Company from GE Healthcare (GEHC), the distributor for ThermoGenesis' AutoXpress and BioArchiver Systems, and brings over twenty years of domestic and international medical technology sales and marketing experience in the specialty surgical, blood banking and stem cell processing markets.Mr. Segal will report directly to Philip H. Coelho, ThermoGenesis' Chairman and Chief Executive Officer.
  ...
  "We believe that Dan will make an immediate contribution to our current leadership position in the cell processing industry as the U.S. government continues to release funds to promote the growth of a national cord blood stem cell banking system and the FDA moves to regulate both the cell therapy products and the devices that enable their manufacture," said Mr. Coelho.
  ...
  During his time with GEHC, Mr. Segal helped establish the Cell Technologies Group.While serving as Business Development Manager of GEHC's Cell Technologies group's North American region, he played a fundamental role in overseeing the multimillion dollar agreement between GEHC and Cord Blood Registry (CBR), the world's largest private cord blood bank.
  
  Mr. Segal commented, "I am eager to return to the Company that first sparked my interest in the life saving potential of cell therapies and the importance of the Company's stem cell banking technologies."
  
  Prior to GEHC, Mr. Segal worked with ThermoGenesis for nearly half of his two decades in the industry during which time he honed his expertise in the stem cell processing and blood banking markets while he helped the Company achieve many milestones.Between 1997 and 2004, Mr. Segal ascended the ranks at ThermoGenesis by leading the Sales & Marketing group and orchestrating sales of the BioArchive Platform products.

• 
  Biobn - Bio Business Networks - Friday Oct 25 2002 - [Cached Version]
  Published on: 2/3/2002    Last Visited: 10/25/2002  

  They have pioneered cord blood banking as a source of readily available stem cells for bone marrow rescue transplants and are the model for the rest of the world's cord blood banks," said Dan Segal, Vice President, Sales & Marketing of ThermoGenesis Corp.
  
  The BioArchive System is used to process, cryopreserve and archive up to 3,626 blood and blood component units.BioArchive Systems have also been chosen by the major cord blood stem cell banks in Japan, China, Taiwan, Vietnam, So.Korea, Malaysia, Germany, Spain, Finland, U.K., Belgium, France, Mexico, India, and Israel as well as in the U.S.A. pursuant to Investigational New Drug ("IND") regulations.The BioArchive System is the international choice for processing and archiving cryopreserved cord blood.
  
  Mr. Segal added, "Cord blood may provide a source of stem cells for tissue regeneration cell therapy unencumbered by the ethical issues involved with harvesting stem cells from embryos or fetuses.We believe our BioArchive Systems position us well in the growing cell therapy market."
  
  Regulatory Status
  
  The BioArchive System is a Class II blood and blood component freezer exempt from the pre-market notification procedures.The BioArchive System has potential applications involving archiving, storing, managing and retrieving other kinds of biological specimens, that may include stem cells, dendritic cells, T-cells, cell lines, sperm cells, eggs, heart valves, corneas, virus samples, biopsy samples and other blood, tissue and saliva samples.

Page:  1 2 3